Low-dose danazol therapy in idiopathic thrombocytopenic purpura.
Low-dose danazol therapy in idiopathic thrombocytopenic purpura.
复制标题
DOI：
10.7326/0003-4819-107-2-177
复制
发表时间：
1987-08
影响因子：
39.2
通讯作者：
Y. Ahn;R. Mylvaganam;R. Garcia;C. Kim;D. Palow;W. Harrington
中科院分区：
文献类型：
--
作者：
Y. Ahn;R. Mylvaganam;R. Garcia;C. Kim;D. Palow;W. Harrington
虽然达那唑治疗特发性血小板减少性紫癜有效，但其长期安全性和最佳剂量尚未得到很好的确定。我们在24例患者中比较了低剂量（50 mg/d）和常规剂量（400 - 800 mg/d）。13例患者在常规剂量停止后1至24个月接受低剂量治疗（1组）。5例患者在常规剂量后立即接受低剂量治疗（2组）。6例患者从一开始就接受低剂量治疗（组3）。在第1组中，9名患者对两种剂量都有类似的反应，而3名患者对常规剂量有更好的反应，1名患者对较低剂量有更好的反应。2组所有患者均维持低剂量缓解。第3组有2个优等回答，1个一般回答，3个差回答。在低剂量的情况下，副作用通常不那么频繁和严重。低剂量达那唑耐受性更好，但需要更长的时间才能获得缓解，并且在特发性血小板减少性紫癜的治疗中用于维持治疗。
Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.